Arecor Therapeutics PLC - Essex, England-based biopharmaceutical company - Granted two patents by the European patent office protecting the company’s formulations of adalimumab until 2038. Adalimumab is a biosimilar of AbbVie Inc’s Humira which treats rheumatoid arthritis and Chohn’s disease.

‘These European patents for high-concentration adalimumab are an important addition to Arecor’s product patent portfolio and provide further proof of the potential of our ArestatTM technology in the development of enhanced biologic products, including high value biosimilars,’ says Chief Executive Sarah Howell.

Current stock price: 309.80 pence

12-month change: up 36%

Copyright 2022 Alliance News Limited. All Rights Reserved.